Original Article
Leukocyte Reduction and Ultraviolet B Irradiation of Platelets to Prevent Alloimmunization and Refractoriness to Platelet Transfusions
N Engl J Med 1997; 337:1861-1870December 25, 1997
- Abstract
Background
We conducted a multi-institutional, randomized, blinded trial to determine whether the use of platelets from which leukocytes had been removed by a filter or that had been treated with ultraviolet B irradiation would prevent the formation of antiplatelet alloantibodies and refractoriness to platelet transfusions.
Methods
Patients who were receiving induction chemotherapy for acute myeloid leukemia were randomly assigned to receive one of four types of platelet transfusions: unmodified, pooled platelet concentrates from random donors (control); filtered, pooled platelet concentrates from random donors (F-PC); ultraviolet B–irradiated, pooled platelet concentrates from random donors (UVB-PC); or filtered platelets obtained by apheresis from single random donors (F-AP). All patients received transfusions of filtered, leukocyte-reduced red cells.
Results
Of 530 patients with no alloantibodies at base line, 13 percent of those in the control group produced lymphocytotoxic antibodies and their thrombocytopenia became refractory to platelet transfusions, as compared with 3 percent in the F-PC group, 5 percent in the UVB-PC group, and 4 percent in the F-AP group (P<0.03 for each treated group as compared with the controls; there were no significant differences among the treated groups). Lymphocytotoxic antibodies were found in 45 percent of the controls, as compared with 17 to 21 percent in the treated groups (P<0.001 for each treated group as compared with the controls; there were no significant differences among the treated groups). Antibodies against platelet glycoproteins developed in 6 to 11 percent of the patients, with no significant differences among the four groups.
Conclusions
Reduction of leukocytes by filtration and ultraviolet B irradiation of platelets are equally effective in preventing alloantibody-mediated refractoriness to platelets during chemotherapy for acute myeloid leukemia. Platelets obtained by apheresis from single random donors provided no additional benefit as compared with pooled platelet concentrates from random donors.
Media in This Article
Figure 3
Development of Alloimmune Platelet Refractoriness in Patients Who Had Refractoriness and Also Were Antibody-Positive.Figure 1
Development of Platelet Refractoriness.Article Activity
- Article
Antibodies against alloantigens on donor platelets are a major cause of refractoriness to platelet transfusions in patients with thrombocytopenia. These antibodies usually arise in response to HLA class I antigens on leukocytes and platelets, and they may result from maternal–fetal incompatibility or repeated blood transfusions. Resources to supply HLA-compatible platelets to patients who have refractoriness to platelet transfusions from random donors are often limited. Moreover, up to 60 percent of transfusions of presumably HLA-compatible platelets fail to increase the platelet count in patients whose thrombocytopenia is refractory to transfusions.1
Previous studies of ways to prevent alloimmunization in patients with thrombocytopenia have been inconclusive.2-8 In this trial we transfused blood components that were modified by leukocyte reduction or ultraviolet B irradiation (to remove or inactivate cells bearing alloantigens, respectively),9-11 or used platelets from single donors (to reduce exposure to multiple HLA antigens).12,13
Methods
Patient Selection
All patients had previously untreated acute myeloid leukemia. The following patients were ineligible for the trial: patients less than 15 years old; patients who were to receive no chemotherapy, low-dose chemotherapy (total doses of less than 90 mg of daunorubicin per square meter of body-surface area, 30 mg of mitoxantrone per square meter, 30 mg of idarubicin per square meter, or 700 mg of cytarabine per square meter), or corticosteroids; recipients of multiple blood transfusions for a hematopoietic disorder two months or more before study entry, or of transfusions from more than 10 different donors between two weeks and two months before study entry; and those given chemotherapy or extensive radiation therapy within the past two years.
The study protocol and consent forms were approved by local institutional review boards.
Randomization
Patients were randomly assigned to receive one of four types of platelet transfusion for eight weeks after the first transfusion of study platelets. The four types of platelet transfusions were unmodified, pooled platelet concentrates from random donors (control); filtered, pooled platelet concentrates from random donors (F-PC); ultraviolet B–irradiated, pooled platelet concentrates from random donors (UVB-PC); and filtered platelets obtained by apheresis from single random donors (F-AP). We refer to the last three types as treated platelets and to the groups of patients who received them as treated groups. Randomization was stratified according to trial site and whether or not subjects had a prior pregnancy or transfusion more than two weeks before enrollment. All patients and investigators, except the study coordinators at the clinical sites, were unaware of the patients' assignments.
Preparation of Blood Components for Transfusion
Blood components were prepared in a blood bank at each trial site. Six units of platelet concentrate prepared from whole-blood, platelet-rich plasma14 were pooled, and if treated, they were filtered or irradiated with ultraviolet B, usually shortly before transfusion. F-AP platelets were collected with a Cobe Spectra apheresis machine (Cobe Laboratories, Lakewood, Colo.) with version 2.6 or 3.6 software.
All patients received filtered red cells to prevent alloimmunization by leukocytes in packed red cells. Filtered blood components were expected to have no more than 5×106 white cells per transfusion. PL-100 filters were used for platelets and either an RC-100 or a BPF-4 filter for red cells (Pall, East Hills, N.Y.). Platelet concentrates were irradiated in a Stericell bag holding 420 ml or less (Dupont, Wilmington, Del.) with a total dose of 1480 mJ per square centimeter with an ultraviolet B irradiator (Haemonetics, Braintree, Mass.).
Transfusions
Prophylactic platelet and red-cell transfusions were given when platelet counts were 20,000 per cubic millimeter or less and hematocrits were 0.25 or less. The assigned transfusions were discontinued only when there were severe adverse reactions, defined as a temperature increase of more than 2°C, shaking chills, extensive urticaria, dyspnea, cyanosis, or bronchospasm. If the patient's assigned platelet component was not available, pooled platelet concentrates were substituted for platelets obtained by apheresis, or vice versa; however, these platelets were treated or not treated according to the patient's randomization assignment. Overall, only 3 percent of the transfusions given were not of the assigned type (3 percent in the control group, 3 percent in the UVB-PC group, 2 percent in the F-PC group, and 5 percent in the F-AP group).
Every six months, ultraviolet B–irradiated platelets from each center were tested by mixed lymphocyte culture. None of these samples contained viable lymphocytes. Platelet and white-cell counts of the platelet preparations were determined after processing by automated cell counters, except for the white-cell counts of the filtered platelet preparations, which were done with propidium iodide staining.15
Calculation of the Corrected Count Increment and Refractoriness to Platelet Transfusions
The corrected count increment was calculated as the difference between the platelet count within an hour after transfusion and the platelet count before transfusion, multiplied by the body-surface area (in square meters) and divided by the number of platelets transfused times 10-11. The mean (±SD) expected corrected count increment in patients receiving transfusions with pooled platelet concentrates from random donors that had been stored for three to five days is approximately 13,500±6000.16 Refractoriness was defined as a corrected count increment of less than 5000 after two sequential transfusions of ABO-compatible platelets, at least one of which had been stored for no more than 48 hours.
Antibody Testing
Serum samples were obtained before entry into the study and weekly thereafter for eight weeks. They were tested for lymphocytotoxic antibodies and antibodies against platelet glycoproteins in central laboratories after the completion of the study. Some patients who were entered into the study were later found to have antiplatelet antibodies in base-line samples, but they were excluded from the primary analyses.
Lymphocytotoxic antibodies against HLA class I antigens were detected with an antiglobulin-augmented, complement-dependent lymphocytotoxicity assay.17 Serum samples were tested against a panel of 30 to 60 HLA-typed frozen cells. Serum samples were considered positive if they reproducibly caused at least 60 percent cytotoxicity in one or more cells or at least 40 percent cytotoxicity in two or more cells in the panel.18 Panel reactivity was calculated as a percentage: the number of positive cells divided by the number of panel cells times 100.
Serum samples were tested for antiplatelet antibodies by intact-platelet enzyme-linked immunosorbent assay (ELISA)19-21 and flow cytometry.22 These assays are sensitive but nonspecific and were used only to screen for antibodies.22,23 The first and most reactive samples from each patient were further tested for antibodies against platelet glycoproteins (GPIIb/IIIa, GPIb/IX, and GPIa/IIa) with a modified antigen-capture ELISA method.24,25
Study End Points
The primary end point was refractoriness to platelet transfusions in patients with lymphocytotoxic antibodies or antibodies against platelet glycoproteins that were detected within two weeks before or after the diagnosis of refractoriness (alloimmune-mediated platelet refractoriness). The secondary end points were refractoriness to platelet transfusions and positive tests for lymphocytotoxic antibodies or antibodies against platelet glycoproteins.
Statistical Analysis
The base-line characteristics of the patients were compared by analysis of variance and the chi-square test. Event rates were estimated by Kaplan–Meier methods over the eight-week study and compared by the log-rank statistic beginning with the first platelet transfusion after randomization. Ninety-five percent confidence intervals estimated with Greenwood's standard errors are reported for event rates. Data on patients were censored at the time of death; no deaths occurred before the first platelet transfusion. Cox regression analyses were used to examine the effect of covariates on the rates of refractoriness and development of lymphocytotoxic antibodies. The factors considered in a multivariate analysis to identify predictors of study end points were treatment assignment, trial site, age, sex, prior pregnancy, whether platelet transfusions were given more or less than two weeks before entry into the study, common HLA type, use of hematopoietic growth factors, and gamma irradiation of more than 50 percent of a patient's transfusions. A parsimonious model was determined for each end point by using forward and backward stepwise procedures in which covariates with P values of less than 0.05 were retained in the final model. Treatment effects and interaction-with-treatment effects were added to the final model by using dummy variables. We performed analyses using calendar time and using the transfusion number as the time variable. All results are reported according to the group to which the patient was randomly assigned.
The power for the study was based on the exponential maximum-likelihood model.26 With 570 randomized patients anticipated, the power to detect a reduction in the rate of alloimmunization from 0.40 to 0.20 at a significance level of 0.05 by two-sided test was 0.92. The trial was sequentially monitored with use of the O'Brien–Fleming method.27
Results
Patients
We screened 1047 patients with acute myeloid leukemia and enrolled 603 of them between January 14, 1991, and February 28, 1995. Patients were excluded because of low-dose chemotherapy or none (36 percent of the screened patients), a prior hematopoietic disorder treated with transfusions (27 percent), prior chemotherapy (20 percent), logistic reasons (14 percent), prior treatment for leukemia (11 percent), refusal to enter the study (11 percent), or administration of corticosteroids (5 percent).
Of the 603 patients who were enrolled, 41 had lymphocytotoxic antibodies at base line, 15 had antibodies against platelet glycoproteins, and 5 had both. Of these 61 patients, 41 (67 percent) had both been previously pregnant and received transfusions. Within this group of 61 patients with antiplatelet antibodies at base line, refractoriness to platelet transfusions was more frequent among patients who had lymphocytotoxic antibodies (55 percent) than among those who did not (10 percent, P<0.001). The presence or absence of antibodies against platelet glycoproteins at base line did not significantly influence the frequency of refractoriness to platelet transfusions (21 percent and 13 percent, respectively; P = 0.17). Study assignment had no significant effect on the development of refractoriness in the antibody-positive patients. These 61 patients were excluded from further analysis, along with 4 patients with no data on base-line antibodies and 8 patients who received fewer than two platelet transfusions.
Table 1Table 1
Patient Characteristics and Prior Exposure to Alloantigens. shows the assignments of the remaining 530 patients into the four study groups. Age, number of pregnancies, and number of prior transfusions were similar in these groups. Base-line hematologic values and type of leukemia were also similar (data not shown). Seventy-five percent of the patients had received transfusions in the two weeks before randomization, and 85 percent of these transfusions were not filtered. Only 12 percent of patients had not received transfusions or been pregnant.Results of Transfusion
Ninety-five percent of the platelet transfusions were ABO-compatible with the recipient. Patients assigned to filtered products received fewer platelets per transfusion because of platelet loss during filtration (P<0.001),28 but the number of platelet transfusions did not differ significantly among the groups (P = 0.18) (Table 2Table 2
Results of Transfusion.).More platelet transfusions with at least 5×106 white cells were given to the F-PC group than to the F-AP group, probably reflecting the lower initial contamination of the apheresis platelets by leukocytes.29 In the UVB-PC group, 1 percent of the platelet transfusions were not irradiated with ultraviolet B. Ninety-eight percent of the red-cell transfusions were filtered, and only 0.5 percent had 5×106 or more white cells per transfusion.
One hundred sixty (2 percent) of the platelet transfusions were associated with a severe adverse reaction, but there were no differences in the frequencies of such reactions among the four groups (P = 0.45, Kruskal–Wallis test). Transfusion reactions led to the withdrawal of only five patients from the study.
Refractoriness to Platelet Transfusions
Among the 530 patients in the study, only 51 (10 percent) met the criteria for refractoriness. Among these 51 patients, Kaplan–Meier estimates (with 95 percent confidence intervals) for the development of refractoriness over the eight weeks of the study were 16 percent (10 to 23 percent) for the control group, 10 percent (6 to 16 percent) for the UVB-PC group, 7 percent (4 to 13 percent) for the F-PC group, and 8 percent (4 to 14 percent) for the F-AP group (P = 0.17, P = 0.03, and P = 0.06, respectively, for the comparison with the control group) (Figure 1Figure 1
Development of Platelet Refractoriness.).Among women who had ever been pregnant, the estimates for the development of refractoriness were 32 percent (21 to 47 percent) for controls as compared with 17 percent (8 to 32 percent) for the UVB-PC group, 10 percent (4 to 22 percent) for the F-PC group, and 16 percent (8 to 29 percent) for the F-AP group (P = 0.10, P = 0.009, and P = 0.09, respectively). Among women who had never been pregnant and men, the rates of refractoriness to platelet transfusions among all four groups were similar and ranged from 3 percent to 6 percent (P>0.26). A rate of 10 percent was noted in patients with and those without a history of transfusions (423 and 107 patients, respectively).
Lymphocytotoxic Antibodies
During the eight weeks of the study, lymphocytotoxic antibodies developed in an estimated 45 percent of the patients in the control group (95 percent confidence interval, 36 to 54 percent), as compared with 21 percent (15 to 30 percent) in the UVB-PC group, 18 percent (12 to 26 percent) in the F-PC group, and 17 percent (12 to 26 percent) in the F-AP group (P<0.001 for each treated group vs. the control group) (Figure 2Figure 2
Development of Lymphocytotoxic Antibodies.). The average (±SD) reactivity of these antibodies with all cells in the test panel was 55±32 percent, with no significant differences among the four groups (P = 0.29). Antibodies were also found in one or two later samples in 89 percent and 80 percent of the patients, respectively.Lymphocytotoxic antibodies developed more frequently in control patients than in patients in any of the treated groups, regardless of whether they had had prior transfusions. Lymphocytotoxic antibodies appeared to develop sooner and at higher rates in women who had ever been pregnant. However, the rate of development of these antibodies was significantly lower among patients receiving treated platelets than among controls, regardless of prior pregnancy. In women who had ever been pregnant, the rate of antibody development was 62 percent in the control group, as compared with 33 percent in the UVB-PC group (P = 0.02), 32 percent in the F-PC group (P = 0.01), and 34 percent in the F-AP group (P = 0.02).
In women who had never been pregnant and in men, the rates of alloimmunization in both the treated groups (10 percent) and the control group (33 percent) were significantly less than in women who had ever been pregnant (P<0.001). The rate of positivity was 32 percent in the control group, as compared with 15 percent in the UVB-PC group (P = 0.01), 9 percent in the F-PC group (P<0.001), and 7 percent in the F-AP group (P<0.001). There were no significant differences among the treated groups.
Antibodies against Platelet Glycoproteins
Overall, antibodies against platelet glycoproteins developed in only 8 percent of patients, and there were no significant differences among the four groups (antibodies developed in 11 percent of control patients, 7 percent of patients in the UVB-PC group, 6 percent of patients in the F-PC group, and 7 percent of patients in the F-AP group).
Alloimmune Platelet Refractoriness
The development of refractoriness to platelet transfusions with antiplatelet antibodies was the primary end point of the study. The Kaplan–Meier estimates for the development of alloimmune platelet refractoriness over the eight weeks of the study (with 95 percent confidence intervals) were 13 percent (8 to 20 percent) for the control group, 5 percent (2 to 11 percent) for the UVB-PC group, 3 percent (1 to 8 percent) for the F-PC group, and 4 percent (2 to 9 percent) for the F-AP group (P = 0.03, P = 0.004, and P = 0.01, respectively, for the comparison with control) (Figure 3Figure 3
Development of Alloimmune Platelet Refractoriness in Patients Who Had Refractoriness and Also Were Antibody-Positive.).Multivariate Analysis
The only factors that lowered the rates of refractoriness to platelet transfusions were treatment assignment (UVB-PC group, P = 0.19; F-PC group, P = 0.02; F-AP group, P = 0.05, for the comparison with control) and absence of prior pregnancy (P<0.001). Absence of prior pregnancy (P<0.001), transfusions given within two weeks before study entry (P = 0.02), and treatment assignment (P<0.001 as compared with control for each treatment) were associated with a lower incidence of lymphocytotoxic antibodies than in the control group. Absence of prior pregnancy (P<0.001) and treatment assignment (UVB-PC group, P = 0.05; F-PC group, P = 0.01; F-AP group, P = 0.01, for the comparison with control) were also associated with lower rates of alloimmune platelet refractoriness.
Similar models were constructed with the transfusion number as the variable. Covariates and P values similar to those in the above analyses were found when calendar time was used.
Clinical Outcomes at Eight Weeks
Seventy-three patients (14 percent) died, and an additional 24 (5 percent) withdrew from the study (Table 3Table 3
Status of Patients during Initial Eight Weeks.). There were no significant differences among the groups in the frequency and causes of death or withdrawal. Three hundred nineteen patients (60 percent) had a complete remission, and the remission rates were similar in all groups.Discussion
We evaluated the development of refractoriness to platelet transfusions and of alloantibodies in patients with thrombocytopenia who received transfusions with treated or control platelets. The patients, who were undergoing chemotherapy for acute myeloid leukemia, received platelets obtained by apheresis from single random donors, pooled concentrates from random donors that had been leukocyte-reduced by filtration, or pooled concentrates from random donors whose leukocytes had been inactivated by ultraviolet B irradiation. There were no significant differences among the three treated groups in any study end point. However, all three types of treated platelets significantly reduced the development of lymphocytotoxic antibodies (P<0.001) and alloimmune refractoriness to platelet transfusions (P<0.03), as compared with untreated, pooled platelet concentrates from random donors. Treated platelets were effective, even though 27 percent of the patients received one or more transfusions of platelets or red cells that did not meet study guidelines, and 88 percent had prior exposure to alloantigens from pregnancy or transfusion. None of the three types of treated platelets affected the development of antibodies against platelet glycoproteins, which, in any case, occurred infrequently, as in other trials.30-32 Patients who had no detectable lymphocytotoxic antibodies at entry into the study benefited from transfusions with treated platelets, whereas patients who had such antibodies did not. For this reason, we recommend transfusion with leukocyte-reduced or ultraviolet B–irradiated platelets only for antibody-negative patients.
In patients who received treated platelets, the incidence of lymphocytotoxic antibodies was lower than in controls, whether or not they had ever been pregnant or received a transfusion. Prior studies33,34 suggested that leukocyte-reduced platelets helped prevent primary immunization but not an anamnestic response; a recent meta-analysis found that the rates of lymphocytotoxic antibodies in patients who had ever been pregnant or received transfusions were lower in patients given leukocyte-reduced platelets and red cells than in controls who received standard blood components.35 Because of strict entry criteria, only 18 percent of our patients had received transfusions more than two weeks before entering the study. Although our data suggest that patients who had received many transfusions could benefit from transfusions of treated platelets, additional studies will have to address this issue. It was anticipated that F-AP platelets might further reduce the incidence of alloimmunization because of exposure to fewer donors,12,13 but there was no evidence of any added benefit as compared with UVB-PC or F-PC platelets.
This study demonstrates that ultraviolet B irradiation and leukocyte reduction give equivalent results. A smaller trial showed a trend toward reduction of alloimmunization with ultraviolet B irradiation.36 Since ultraviolet B irradiation is a relatively new method of treating platelets, we attempted to verify the clinical efficacy of ultraviolet B–treated platelets.37-40 Although the values for the corrected count increment in recipients of ultraviolet B–treated platelets were slightly reduced, the number of platelet transfusions required in these patients was the same as for the other groups, and the clinical outcomes were also similar.
We studied patients with acute myeloid leukemia because they require repeated transfusions of platelets and because alloimmunization can hinder potentially curative therapy. Determining whether our results are applicable to patients who are receiving less intensive chemotherapy or who have a normal immune system, such as patients with aplastic anemia, will require additional studies.41,42
The frequency of refractoriness to platelet transfusions in this study was surprisingly low, perhaps because we excluded patients who were transiently refractory because of causes other than immunization or who were responsive to transfusions of ABO-compatible or fresh platelets.43 In all groups, the incidence of alloantibodies was considerably higher than the incidence of refractoriness to platelet transfusions. For example, in 29 percent of the patients in the control group, lymphocytotoxic antibodies developed without evidence of refractoriness to platelet transfusions; corresponding values were 14 percent in the UVB-PC group, 12 percent in the F-PC group, and 12 percent in the F-AP group. Thus, for some patients, the development of antiplatelet alloantibodies did not necessarily result in refractoriness to platelet transfusion. Lymphocytotoxic antibodies of restricted specificity may not react against transfused incompatible donor antigens. Moreover, lymphocytotoxic antibodies were often first detected three to four weeks after entry into the study (Figure 2), when some patients were no longer receiving platelet transfusions. Such patients could not have been evaluated for the effects of the antibody on transfused platelets. Nevertheless, avoidance of lymphocytotoxic antibodies should benefit patients during subsequent chemotherapy, since there is a close relation between these antibodies and refractoriness to platelet transfusions.44 Some patients were refractory to platelet transfusions and did not have lymphocytotoxic antibodies. They accounted for 3 percent of the patients in the control group and 4 percent of the patients in each of the treated groups. These patients most likely had adverse clinical factors or drug-related causes of refractoriness.45,46
The clinical outcomes were essentially the same among all four groups of the study. Specifically, overall death rates were similar, and there were no significant differences among these groups in the incidence of death due to hemorrhage, infection, or refractory leukemia. Few patients withdrew from the study, and the overall proportion of patients in complete remission at the end of the eight weeks of observation was 60 percent.
Whether leukocyte reduction or ultraviolet B irradiation should be the primary method of preventing platelet alloimmunization may depend on costs and other considerations. Filtration reduces the risk of infection from viruses harbored by leukocytes, such as cytomegalovirus.47 Ultraviolet A irradiation used with photoadditive agents has shown promise in reducing the risk of infection from bacterial and viral contaminants in platelets for transfusion48 and may replace gamma irradiation as a method of preventing transfusion-associated graft-versus-host disease.49
Whether our results could be improved on by prestorage leukocyte reduction50 or a combination of ultraviolet B irradiation and leukocyte reduction remains to be determined.51,52 Interestingly, lymphocytotoxic antibodies developed in 19 percent of the 36 patients with no prior alloantigen exposure who received treated transfusions according to all study guidelines. Prevention of alloimmunization in such patients remains a challenge that requires further study.
Supported by grants (U01 HL42799, U01 HL42802, U01 HL42805, U01 HL42810, U01 HL42811, U01 HL42815, U01 HL42824, and U01 HL42832) from the National Heart, Lung, and Blood Institute, National Institutes of Health.
Dr. Slichter assumes responsibility for the overall content and integrity of the manuscript.
We are indebted to Ginny Knight, Puget Sound Blood Center, Seattle, for excellent secretarial assistance.
Source Information
Address reprint requests to Dr. Sherrill J. Slichter at the Division of Research and Education, Puget Sound Blood Center, 921 Terry Ave., Seattle, WA 98104-1256.
The members of the Trial to Reduce Alloimmunization to Platelets (TRAP) Study Group are listed in the Appendix.
Appendix
The following persons and institutions participated in the National Heart, Lung, and Blood Institute TRAP study.
Clinical centers — Blood Center of Southeastern Wisconsin: J. McFarland, J. Menitove, and L. Kagen; Johns Hopkins University: H. Braine, T. Kickler, P. Ness, and A. Fuller; Puget Sound Blood Center: S. Slichter, T. Gernsheimer, and D. Townsend-McCall; University of Florida: K.-J. Kao, W. Noyes, R. Weiner, S. Hudson, and A. Waldman-Slone; University of Maryland Cancer Center, University of Maryland School of Medicine: C. Schiffer, E. Lee, and D. Norris; University of Minnesota: J. McCullough, H. Enright, S. Lennon, and M. Clay; University of Wisconsin: R. Woodson, M. Meisch, and P. Noordsij. Coordinating center — University of Washington: K. Davis, M. Mickel, M.J. Gillespie, G. Ng, S. Parker, and S. Corley. Histocompatibility central laboratory — Emory University: G. Rodey. Platelet immunology central laboratory — Blood Center of Southeastern Wisconsin: J. McFarland. Quality control laboratory for platelet and white-cell counting — University of Florida: K.-J. Kao. Chairman of Steering Committee: K. Sell, Emory University. National Heart, Lung, and Blood Institute: G. Nemo, D. Follmann, M. Hernandez, and C. Hollingsworth. Data and Safety Monitoring Committee: H. Klein (chairman), J. Dutcher, J. Frantantoni, M. Kruskall, R. Macklin, R. Strauss, and J. Wittes.
- References
References
1
Duquesnoy RJ ,Filip DJ ,Rodey GE ,Rimm AA ,Aster RH . Successful transfusion of platelets “mismatched“ for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977;2:219-226
CrossRef | Web of Science | Medline2
Schiffer CA ,Dutcher JP ,Aisner J ,Hogge D ,Wiernik PH ,Reilly JP . A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815-820
Web of Science | Medline3
Murphy MF ,Metcalfe P ,Thomas H , et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol 1986;62:529-534
CrossRef | Web of Science | Medline4
Sniecinski I ,O'Donnell MR ,Nowicki B ,Hill LR . Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402-1407
Web of Science | Medline5
Andreu G ,Dewailly J ,Leberre C , et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964-969
Web of Science | Medline6
Oksanen K ,Kekomaki R ,Ruutu T ,Koskimies S ,Myllyla G . Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components -- a randomized trial. Transfusion 1991;31:588-594
CrossRef | Web of Science | Medline7
van Marwijk Kooy M ,van Prooijen HC ,Moes M ,Bosma-Stants I ,Akkerman JWN . The use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991;77:201-205
Web of Science | Medline8
Williamson LM ,Wimperis JZ ,Williamson P . Bedside filtration of blood products in the prevention of HLA alloimmunization -- a prospective randomized study: Alloimmunization Study Group. Blood 1994;83:3028-3035
Web of Science | Medline9
Claas FHJ ,Smeenk RJT ,Schmidt R ,van Steenbrugge GJ ,Eernisse JG . Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981;9:84-89
Web of Science | Medline10
Kripke ML . Immunologic unresponsiveness induced by ultraviolet radiation. Immunol Rev 1984;80:87-102
CrossRef | Web of Science | Medline11
Lindahl-Kiessling K ,Safwenberg J . Inability of UV-irradiated lymphocytes to stimulate allogeneic cells in mixed lymphocyte culture. Int Arch Allergy Appl Immunol 1971;41:670-678
CrossRef | Medline12
Gmur J ,von Felten A ,Osterwalder B , et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 1983;62:473-479
Web of Science | Medline13
Sintnicolaas K ,Vriesendorp HM ,Sizoo W , et al. Delayed alloimmunisation by random single donor platelet transfusions: a randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia. Lancet 1981;1:750-754
CrossRef | Web of Science | Medline14
Murphy S ,Heaton WA ,Rebulla P . Platelet production in the old world -- and the new. Transfusion 1996;36:751-754
CrossRef | Web of Science | Medline15
Kao KJ ,Scornik JC . Accurate quantitation of the low number of white cells in white cell-depleted blood components. Transfusion 1989;29:774-777
CrossRef | Web of Science | Medline16
Schiffer CA ,Lee EJ ,Ness PM ,Reilly J . Clinical evaluation of platelet concentrates stored for one to five days. Blood 1986;67:1591-1594
Web of Science | Medline17
Fuller TC ,Phelan DL ,Gebel HM ,Rodey GE . Antigenic specificity of antibody reactive in the antiglobulin-augmented lymphocytotoxicity test. Transplantation 1982;34:24-29
CrossRef | Web of Science | Medline18
Terasaki PI ,Bernoco D ,Park MS ,Ozturk G ,Iwaki Y . Microdroplet testing for HLA-A, -B, -C, and -D antigens: the Phillip Levine Award Lecture. Am J Clin Pathol 1978;69:103-120
Web of Science | Medline19
Schiffer CA ,Young V . Detection of platelet antibodies using a micro-enzyme-linked immunosorbent assay (ELISA). Blood 1983;61:311-317
Web of Science | Medline20
Howe SE ,Lynch DM ,Lynch JM . An enzyme-linked immunosorbent assay for the quantification of serum platelet-bindable IgG. Transfusion 1984;24:348-352
CrossRef | Web of Science | Medline21
Collins J ,Aster RH . Use of immobilized platelet membrane glycoproteins for the detection of platelet-specific alloantibodies in solid-phase ELISA. Vox Sang 1987;53:157-161
CrossRef | Web of Science | Medline22
Visentin GP ,Wolfmeyer K ,Newman PJ ,Aster RH . Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 1990;30:694-700
CrossRef | Web of Science | Medline23
Curtis BR ,McFarland JG ,Wu GG ,Visentin GP ,Aster RH . Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood 1994;84:176-183
Web of Science | Medline24
Furihata K ,Nugent DJ ,Bissonette A ,Aster RH ,Kunicki TJ . On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa: evidence for heterogeneity of glycoprotein IIIa. J Clin Invest 1987;80:1624-1630
CrossRef | Web of Science | Medline25
Kekomaki R ,Dawson B ,McFarland J ,Kunicki TJ . Localization of human platelet autoantigens to the cysteine-rich region of glycoprotein IIIa. J Clin Invest 1991;88:847-854
CrossRef | Web of Science | Medline26
Rubinstein LV ,Gail MH ,Santner TJ . Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 1981;34:469-479
CrossRef | Medline27
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline28
Kao KJ ,Mickel M ,Braine HG , et al. White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. Transfusion 1995;35:13-19
CrossRef | Web of Science | Medline29
Lutz P ,Dzik WH . Large-volume hemocytometer chamber for accurate counting of white cells (WBCs) in WBC-reduced platelets: validation and application for quality control of WBC-reduced platelets prepared by apheresis and filtration. Transfusion 1993;33:409-412
CrossRef | Web of Science | Medline30
Kickler TS ,Kennedy SD ,Braine HG . Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990;30:622-625
CrossRef | Web of Science | Medline31
Brand A ,van Leeuwen A ,Eernisse JG ,van Rood JJ . Platelet transfusion therapy: optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests. Blood 1978;51:781-788
Web of Science | Medline32
Kickler TS ,Braine HG ,Ness PM . The predictive value of platelet crossmatching. Transfusion 1985;25:385-389
CrossRef | Web of Science | Medline33
Brand A ,Claas FHJ ,Voogt PJ ,Wasser MNJM ,Eernisse JG . Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988;54:160-166
CrossRef | Web of Science | Medline34
Sintnicolaas K ,van Marwijk Kooij M ,van Prooijen HC , et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824-828
Web of Science | Medline35
Andreu G ,Dewailly J . Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hematol Blood Transfus 1994;60:29-40
Medline36
Blundell EL ,Pamphilon DH ,Fraser ID , et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996;36:296-302
CrossRef | Web of Science | Medline37
Andreu G ,Boccaccio C ,Lecrubier C , et al. Ultraviolet irradiation of platelet concentrates: feasibility in transfusion practice. Transfusion 1990;30:401-406
CrossRef | Web of Science | Medline38
Grijzenhout MA ,Aarts-Riemens MI ,de Gruijl FR ,van Weelden H ,van Prooijen HC . UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients. Blood 1994;84:3524-3531
Web of Science | Medline39
Pamphilon DH ,Potter M ,Cutts M , et al. Platelet concentrates irradiated with ultraviolet light retain satisfactory in vitro storage characteristics and in vivo survival. Br J Haematol 1990;75:240-244
CrossRef | Web of Science | Medline40
Sherman L ,Menitove J ,Kagen LR , et al. Ultraviolet-B irradiation of platelets: a preliminary trial of efficacy. Transfusion 1992;32:402-407
CrossRef | Web of Science | Medline41
Holohan TV ,Terasaki PI ,Deisseroth AB . Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981;58:122-128
Web of Science | Medline42
Lee EJ ,Schiffer CA . Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987;70:1727-1729
Web of Science | Medline43
Norol F ,Kuentz M ,Cordonnier C , et al. Influence of clinical status on the efficacy of stored platelet transfusion. Br J Haematol 1994;86:125-129
CrossRef | Web of Science | Medline44
Hogge DE ,Dutcher JP ,Aisner J ,Schiffer CA . Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. Am J Hematol 1983;14:363-369
CrossRef | Web of Science | Medline45
Friedberg RC ,Donnelly SF ,Boyd JC ,Gray LS ,Mintz PD . Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81:3428-3434
Web of Science | Medline46
Bishop JF ,McGrath K ,Wolf MM , et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383-387
Web of Science | Medline47
Bowden RA ,Slichter SJ ,Sayers M , et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-3603
Web of Science | Medline48
Corash L ,Cook D ,Reames A ,Arnstein P . Photochemical decontamination of platelet concentrates prevents transfusion induced cytomegalovirus infection. Blood 1994;84:Suppl 1:530a-530a abstract.
Web of Science49
Grass J ,Hei D ,Wiesehahn GP ,Corash L ,Lin L . Inactivation of T-cells with psoralens and UVA in human platelet concentrates. Blood 1995;86:Suppl 1:542a-542a abstract.50
Blajchman MA . The effect of leukodepletion on allogeneic donor platelet survival and refractoriness in an animal model. Semin Hematol 1991;28:Suppl 5:14-17
Web of Science | Medline51
Grijzenhout MA ,Aarts-Riemens MI ,Claas FHJ ,van Prooijen HC . Prevention of MHC-alloimmunization by UV-B irradiation in a murine model: effects of UV dose and number of transfused cells. Br J Haematol 1994;87:598-604
CrossRef | Web of Science | Medline52
Fish D ,Abrams K ,Slichter SJ . Prevention of alloimmune platelet (PLT) refractoriness in a dog PLT transfusion (TX) model requires both leukocyte (WBC) reduction plus either red blood cell (RBC) reduction or ultraviolet-B (UV-B) irradiation. Blood 1995;86:Suppl 1:541a-541a abstract.
- Citing Articles (252)
Citing Articles
1
Christopher R. Gilson, Seema R. Patel, James C. Zimring. (2012) Cytotoxic T-lymphocyte-associated antigen 4 with a modified constant region of human immunoglobulin G1 prevents alloantibody production and bone marrow transplant rejection in response to platelet transfusions in mice. Transfusionno-no
CrossRef2
S Yoshihara, K Taniguchi, H Ogawa, H Saji. (2012) The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA?. Bone Marrow Transplantation
CrossRef3
Naomi L.C. Luban, Eileen McBride, Jason C. Ford, Sumit Gupta. (2012) Transfusion medicine problems and solutions for the pediatric hematologist/oncologist. Pediatric Blood & Cancern/a-n/a
CrossRef4
Gowrie S. Balasubramaniam, Matthew Morris, Arun Gupta, Irene Rebello Mesa, Raj Thuraisingham, Neil Ashman. (2012) Allosensitization Rate of Male Patients Awaiting First Kidney Grafts After Leuko-Depleted Blood Transfusion. Transplantation1
CrossRef5
2011. Clinical Uses of Blood Components. , 238-304.
CrossRef6
2011. Transfusion Therapy in Specific Clinical Situations. , 305-361.
CrossRef7
O. Erhabor, T.C. Adias. (2011) From whole blood to component therapy: The economic, supply/demand need for implementation of component therapy in sub-Saharan Africa. Transfusion Clinique et Biologique 18:5-6, 516-526
CrossRef8
M. B. C. Koh, Y. S. Lee, J. Chay. (2011) Appropriate blood component usage. ISBT Science Series 6:2, 249-256
CrossRef9
Maxime Berthelot-Richer, Brigitte Boilard, Annie Morin, Brigitte Bolduc, Patrice Beauregard, Rami Kotb. (2011) Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. Transfusionno-no
CrossRef10
S. K. Harm, J. S. Raval, J. Cramer, J. H. Waters, M. H. Yazer. (2011) Hemolysis and sublethal injury of RBCs after routine blood bank manipulations. Transfusion Medicineno-no
CrossRef11
Áine Honohan, Bert Tomson, Johanna van der Bom, René de Vries, Anneke Brand. (2011) A comparison of volume-reduced versus standard HLA/HPA-matched apheresis platelets in alloimmunized adult patients. Transfusionno-no
CrossRef12
Christopher R. Gilson, James C. Zimring. (2011) Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model. Transfusionno-no
CrossRef13
Monique P. Gelderman, Xuan Chi, Li Zhi, Jaroslav G. Vostal. (2011) Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion. Transfusion 51:11, 2343-2357
CrossRef14
Rosa Sanchez, Tzong-Hae Lee, Li Wen, Leilani Montalvo, Cathy Schechterly, Camilla Colvin, Harvey J. Alter, Naomi L.C. Luban, Michael P. Busch. (2011) Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusionno-no
CrossRef15
Laurence Corash. (2011) Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Review of Hematology 4:5, 509-525
CrossRef16
Benjamin Rioux-Massé, Jeffrey McCullough. (2011) The role of the pretransfusion platelet count in platelet refractoriness. Transfusion 51:10, 2258-2259
CrossRef17
Lise J. Estcourt, S. J. Stanworth, M. F. Murphy. (2011) Platelet transfusions for patients with haematological malignancies: who needs them?. British Journal of Haematology 154:4, 425-440
CrossRef18
Joshua J. Chern, Andrew J. Tsung, William Humphries, Raymond Sawaya, Frederick F. Lang. (2011) Clinical outcome of leukemia patients with intracranial hemorrhage. Journal of Neurosurgery 115:2, 268-272
CrossRef19
Abbas Habibi, Mohsen Esfandbod, Mohammad Hossein Ghafari, Patricia Khashayar, Atabak Najafi, Reza Shariat Moharari. (2011) Platelet kinetics after slow versus standard transfusions: A pilot study. Upsala Journal of Medical Sciences 116:3, 212-215
CrossRef20
I. Branco. (2011) Tailored blood collections. ISBT Science Series 6:1, 136-141
CrossRef21
Paolo Perseghin. (2011) High concentration plasma-reduced plateletapheresis concentrates. Transfusion and Apheresis Science 44:3, 273-276
CrossRef22
Lizabeth Rosenbaum, Peter Tomasulo, Karen Shoos Lipton, Paul Ness. (2011) The reintroduction of nonleukoreduced blood: would patients and clinicians agree?. Transfusionno-no
CrossRef23
Torunn O. Apelseth, Tor Hervig, Øystein Bruserud. (2011) Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia. Blood Reviews 25:3, 113-122
CrossRef24
Zoe K. McQuilten, Nikita Schembri, Mark N. Polizzotto, Christine Akers, Melissa Wills, Merrole F. Cole-Sinclair, Susan Whitehead, Erica M. Wood, Louise E. Phillips. (2011) Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study. Transfusion 51:5, 943-948
CrossRef25
Cassandra D. Josephson, Simone A. Glynn, Steve H. Kleinman, Morris A. Blajchman. (2011) A multidisciplinary “think tank”: the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium. Transfusion 51:4, 828-841
CrossRef26
Rohini Radia, Derwood Pamphilon. (2011) Transfusion strategies in patients undergoing stem-cell transplantation. Expert Review of Hematology 4:2, 213-220
CrossRef27
Sherrill J. Slichter, Douglas Bolgiano, Kuo-Jang Kao, Thomas S. Kickler, Janice McFarland, Jeffrey McCullough, Robert Woodson. (2011) Persistence of Lymphocytotoxic Antibodies in Patients in the Trial to Reduce Alloimmunization to Platelets: Implications for Using Modified Blood Products. Transfusion Medicine Reviews 25:2, 102-110
CrossRef28
Jean-Pierre Cazenave, Hervé Isola, Chantal Waller, Isabelle Mendel, Daniel Kientz, Michel Laforêt, Jean-Pierre Raidot, Gérard Kandel, Marie-Louise Wiesel, Laurence Corash. (2011) Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 51:3, 622-629
CrossRef29
Nancy M. Heddle, Donald M. Arnold, Kathryn E. Webert. (2011) Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion 51:2, 430-434
CrossRef30
James C. Zimring, Lis Welniak, John W. Semple, Paul M. Ness, Sherrill J. Slichter, Steven L. Spitalnik, . (2011) Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group. Transfusion 51:2, 435-441
CrossRef31
Axel Seltsam, Thomas H. Müller. (2011) UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma. Transfusion Medicine and Hemotherapy 38:1, 43-54
CrossRef32
J McCullough. 2011. Transfusion medicine for pathologists. , 619-639.
CrossRef33
Jeffrey McCullough. (2010) Innovation in transfusion medicine and blood banking: documenting the record in 50 years of TRANSFUSION. Transfusion 50:12, 2542-2546
CrossRef34
C. R. Gilson, C. M. Cadwell, N. H. Smith, J. E. Hendrickson, J. C. Zimring. (2010) MHC II on transfused murine blood is not required for alloimmunization against MHC I. Vox Sanguinis 99:4, 369-374
CrossRef35
Susanne Marschner, Loren D. Fast, William M. Baldwin III, Sherrill J. Slichter, Raymond P. Goodrich. (2010) White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 50:11, 2489-2498
CrossRef36
Marcela Contreras, Clare PF Taylor, John A Barbara. 2010. Clinical Blood Transfusion. , 268-299.
CrossRef37
Meghan Delaney, Erin Meyer, Christine Cserti-Gazdewich, Richard L. Haspel, Yulia Lin, Anna Morris, Katerina Pavenski, Walter H. Dzik, Mike Murphy, Sherrill Slichter, Grace Wang, Larry J. Dumont, Nancy Heddle. (2010) A systematic assessment of the quality of reporting for platelet transfusion studies. Transfusion 50:10, 2135-2144
CrossRef38
Cindy M. Chang, Scott C. Quinlan, Joan L. Warren, Eric A. Engels. (2010) Blood transfusions and the subsequent risk of hematologic malignancies. Transfusion 50:10, 2249-2257
CrossRef39
Morris A. Blajchman, Simone A. Glynn, Cassandra D. Josephson, Steve H. Kleinman. (2010) Clinical Trial Opportunities in Transfusion Medicine: Proceedings of a National Heart, Lung, and Blood Institute State-of-the-Science Symposium. Transfusion Medicine Reviews 24:4, 259-285
CrossRef40
Judith Marsh, Gerard Socie, Andre Tichelli, Hubert Schrezenmeier, Britta Hochsmann, Antonio M. Risitano, Monika Fuehrer, Albert N. Bekassy, Elizabeth T. Korthof, Anna Locasciulli, Per Ljungman, Andrea Bacigalupo, Bruce Camitta, Neal S. Young, Jakob Passweg, . (2010) Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia. British Journal of Haematology 150:3, 377-379
CrossRef41
H. Schrezenmeier, E. Seifried. (2010) Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?. Vox Sanguinis 99:1, 1-15
CrossRef42
Jeffrey McCullough. (2010) Overview of Platelet Transfusion. Seminars in Hematology 47:3, 235-242
CrossRef43
Sarah Marktel, Sara Napolitano, Elisabetta Zino, Barbara Cappelli, Robert Chiesa, Francesca Poli, Roberto Crocchiolo, Paola Ronchi, Silvano Rossini, Fabio Ciceri, Maria G. Roncarolo, Katharina Fleischhauer. (2010) Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Pediatric Transplantation 14:3, 393-401
CrossRef44
GREGORY J. LATHAM, ROBERT S. GREENBERG. (2010) Anesthetic considerations for the pediatric oncology patient - part 2: systems-based approach to anesthesia. Pediatric Anesthesia 20:5, 396-420
CrossRef45
Seth Eisenberg. (2010) Refractory Response to Platelet Transfusion Therapy. Journal of Infusion Nursing 33:2, 89-97
CrossRef46
H. Dohner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Buchner, A. K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, F. Lo-Coco, T. Naoe, D. Niederwieser, G. J. Ossenkoppele, M. A. Sanz, J. Sierra, M. S. Tallman, B. Lowenberg, C. D. Bloomfield. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:3, 453-474
CrossRef47
Rachael P. Jackman, John W. Heitman, Susanne Marschner, Raymond P. Goodrich, Philip J. Norris. (2009) IMMUNOHEMATOLOGY: Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment. Transfusion 49:12, 2686-2699
CrossRef48
Harald Mohr, Leif Steil, Ute Gravemann, Thomas Thiele, Elke Hammer, Andreas Greinacher, Thomas H. Müller, Uwe Völker. (2009) A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 49:12, 2612-2624
CrossRef49
Seema R. Patel, Chantel M. Cadwell, Arielle Medford, James C. Zimring. (2009) Transfusion of minor histocompatibility antigen–mismatched platelets induces rejection of bone marrow transplants in mice. Journal of Clinical Investigation 119:9, 2787-2794
CrossRef50
Darrell J. Triulzi, Steven Kleinman, Ram M. Kakaiya, Michael. P. Busch, Philip J. Norris, Whitney R. Steele, Simone A. Glynn, Christopher D. Hillyer, Patricia Carey, Jerome L. Gottschall, Edward L. Murphy, Jorge A. Rios, Paul M. Ness, David J. Wright, Danielle Carrick, George B. Schreiber. (2009) The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 49:9, 1825-1835
CrossRef51
Jean Claude Osselaer, Chantal Doyen, Laurence Defoin, Cecile Debry, Maité Goffaux, Nathalie Messe, Maryse Van Hooydonk, Andre Bosly, Jin Sying Lin, Lily Lin, Laurence Corash. (2009) Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 49:7, 1412-1422
CrossRef52
Myra Coppage, Marc Baker, Lawrence Fialkow, Danielle Meehan, Kelly Gettings, Leway Chen, H. Todd Massey, Neil Blumberg. (2009) Lack of significant de novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products. Human Immunology 70:6, 413-416
CrossRef53
Raymond P. Goodrich, Denise Gilmour, Nick Hovenga, Shawn D. Keil. (2009) A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 49:6, 1205-1216
CrossRef54
Jeanne E. Hendrickson, Christopher D. Hillyer. (2009) Noninfectious Serious Hazards of Transfusion. Anesthesia & Analgesia 108:3, 759-769
CrossRef55
J. Cid, L. Ramiro, L. Escoda, A. Llorente. (2009) Efficacy of transfusion of platelet concentrates obtained by manual pooling or by semiautomated pooling of buffy-coats: a retrospective analysis of count increment, corrected count increment and transfusion interval. Vox Sanguinis 96:1, 29-33
CrossRef56
Jelena L. Holovati, Judith L. Hannon, Maria I.C. Gyongyossy-Issa, Jason P. Acker. (2009) Blood Preservation Workshop: New and Emerging Trends in Research and Clinical Practice. Transfusion Medicine Reviews 23:1, 25-41
CrossRef57
Jungwon Hyun, Young Mi Lim, Kyung Deuk Park, Bok Youn Han, Yang Hyun Kim, Kyou Sup Han, Myoung Hee Park. (2009) An Evaluation of Platelet Transfusion Response Using HLA Crossmatch-compatible Donors in Patients with Platelet Refractoriness. The Korean Journal of Laboratory Medicine 29:5, 481
CrossRef58
Souichi Shiratori, Takeshi Kondo, Kentaro Wakasa, Makoto Ibata, Yusuke Shono, Mutsumi Takahata, Akio Shigematsu, Tomomi Toubai, Naoko Kato, Shuichi Ota, Kaoru Kahata, Yukari Takeda, Norihiro Sato, Junji Tanaka, Masahiro Asaka, Masahiro Imamura. (2009) EFFICACY OF GRANULOCYTE TRANSFUSION FOR SEVERE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION AFTER HIGH-DOSE CYTARABINE FOR ACUTE MYELOGENOUS LEUKEMIA. Japanese Journal of Transfusion and Cell Therapy 55:1, 37-42
CrossRef59
J HENDRICKSON. 2009. Platelet Transfusion Refractory Patients. , 283-286.
CrossRef60
J ZIMRING. 2009. Leukoreduction of Blood Products. , 215-218.
CrossRef61
Gregory A. Denomme, Willy A. Flegel. (2008) Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion 48:11, 2461-2475
CrossRef62
J. L. Gajewski, V. V. Johnson, S. G. Sandler, A. Sayegh, T. R. Klumpp. (2008) A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 112:8, 3036-3047
CrossRef63
John W. Semple, Edwin R. Speck, Antonio Fabron Jr, Rukhsana Aslam Michael Kim, John Freedman. (2008) A novel immunosuppressive pathway involving peroxynitrate-mediated nitration of platelet antigens within antigen-presenting cells. Transfusion 48:9, 1917-1924
CrossRef64
Rukhsana Aslam, Edwin R. Speck, Michael Kim, John Freedman, John W. Semple. (2008) Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells. Transfusion 48:9, 1778-1786
CrossRef65
MARLOES WAANDERS, LEO VAN DE WATERING, ANNEKE BRAND. (2008) Immunomodulation and allogeneic blood transfusion. Transfusion Alternatives in Transfusion Medicine 10:3, 127-138
CrossRef66
Jean-Louis H. Kerkhoffs, Jeroen C.J. Eikenboom, Leo M.G. van de Watering, Rinie J. van Wordragen-Vlaswinkel, Pierre W. Wijermans, Anneke Brand. (2008) The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 48:9, 1959-1965
CrossRef67
Christopher D. Hillyer, Neil Blumberg, Simone A. Glynn, Paul M. Ness, . (2008) Transfusion recipient epidemiology and outcomes research: possibilities for the future. Transfusion 48:8, 1530-1537
CrossRef68
Eldad Hod, Joseph Schwartz. (2008) Platelet transfusion refractoriness. British Journal of Haematology 142:3, 348-360
CrossRef69
(2008) Sporadic leukoreduction filter failure during red blood cell component preparation: beware of rapid filtration. Transfusion 48:8, 1766-1767
CrossRef70
B. Zhou, S. Saito, Y. Nakazawa, N. Kobayashi, M. Matsuda, Y. Matsumoto, T. Hosoyama, K. Koike. (2008) Existence of an immunoglobulin G component of naturally occurring HLA class I antibodies that are not directed against self-antigens in human serum. Tissue Antigens 72:2, 98-104
CrossRef71
Nancy M. Heddle, Donald M. Arnold, Diana Boye, Kathryn E. Webert, Ilona Resz, Larry J. Dumont. (2008) Comparing the efficacy and safety of apheresis and whole bloodderived platelet transfusions: a systematic review. Transfusion 48:7, 1447-1458
CrossRef72
J. Bux. (2008) Leucocyte antibody-mediated transfusion reactions. ISBT Science Series 3:1, 161-163
CrossRef73
N. M. Heddle. (2008) The value of evidence-based medicine. ISBT Science Series 3:1, 1-7
CrossRef74
M. M. Mueller, R. Henschler, E. Seifried. (2008) Clinical impact of leucocyte depletion – what is the evidence?. ISBT Science Series 3:1, 85-90
CrossRef75
Dominik Heim, Jakob Passweg, Michael Gregor, Andreas Buser, Alexander Theocharides, Caroline Arber, Sandrine Meyer-Monard, Jörg Halter, Andre Tichelli, Alois Gratwohl. (2008) Patient and product factors affecting platelet transfusion results. Transfusion 48:4, 681-687
CrossRef76
Franz Weinauer. (2008) Supply with Platelet Concentrates from the Point of View of a Blood Donation Service of the Bavarian Red Cross. Transfusion Medicine and Hemotherapy 35:2, 114-116
CrossRef77
Hans-Gert Heuft, Wolfgang Mende, Rainer Blasczyk. (2008) A General Change of the Platelet Transfusion Policy from Apheresis Platelet Concentrates to Pooled Platelet Concentrates is Associated with a Sharp Increase in Donor Exposure and Infection Rates. Transfusion Medicine and Hemotherapy 35:2, 106-113
CrossRef78
Dean A Follmann. 2007. Primary Efficacy Endpoint. .
CrossRef79
Ralph R Vassallo. (2007) New paradigms in the management of alloimmune refractoriness to platelet transfusions. Current Opinion in Hematology 14:6, 655-663
CrossRef80
Hiroshi Asano, Chih-Yuan Lee, Karen Fox-Talbot, Cheryl M. Koh, Melek M. Erdinc, Susanne Marschner, Shawn Keil, Raymond P. Goodrich, William M. Baldwin. (2007) Treatment With Riboflavin and Ultraviolet Light Prevents Alloimmunization to Platelet Transfusions and Cardiac Transplants. Transplantation 84:9, 1174-1182
CrossRef81
J. S. Cervia, B. Wenz, G. A. Ortolano. (2007) Leukocyte Reduction's Role in the Attenuation of Infection Risks among Transfusion Recipients. Clinical Infectious Diseases 45:8, 1008-1013
CrossRef82
Kathryn E. Webert, Richard J. Cook, Stephen Couban, Julie Carruthers, Ker-Ai Lee, Morris A. Blajchman, Jeffrey H. Lipton, Joseph M. Brandwein, Nancy M. Heddle. (2007) A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion 0:0, 071003012013009-???
CrossRef83
E Gurkan, P A Patah, R M Saliba, C A Ramos, B S Anderson, R Champlin, M de Lima, B Lichtiger. (2007) Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation 40:5, 461-464
CrossRef84
David F Stroncek, Paolo Rebulla. (2007) Platelet transfusions. The Lancet 370:9585, 427-438
CrossRef85
Sherrill J. Slichter. (2007) Platelet Transfusion Therapy. Hematology/Oncology Clinics of North America 21:4, 697-729
CrossRef86
N. M. Heddle. (2007) Controversy concerning platelet dose. ISBT Science Series 2:1, 220-225
CrossRef87
Porselvi Chockalingam, Ronald A. Sacher. (2007) Management of Patients Refractory to Platelet Transfusion. Journal of Infusion Nursing 30:4, 220-225
CrossRef88
Stavros G. Drakos, James C. Stringham, James W. Long, Edward M. Gilbert, Thomas C. Fuller, Beverly K. Campbell, Benjamin D. Horne, Mary E. Hagan, Karl E. Nelson, Judy M. Lindblom, Patty A. Meldrum, Joanne F. Carlson, Stephanie A. Moore, Abdallah G. Kfoury, Dale G. Renlund. (2007) Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: The impact of leukofiltered cellular blood product transfusions. The Journal of Thoracic and Cardiovascular Surgery 133:6, 1612-1619
CrossRef89
Mark Ignatz, Martha Sola-Visner, Lisa M. Rimsza, Debra Fuchs, Jonathan J. Shuster, Xiao-Miao Li, Anil Jotwani, Susan Staba, John R. Wingard, Zhongbo Hu, William B. Slayton. (2007) Umbilical Cord Blood Produces Small Megakaryocytes After Transplantation. Biology of Blood and Marrow Transplantation 13:2, 145-150
CrossRef90
Bruce Cameron, Gail Rock, Bernard Olberg, Doris Neurath. (2007) Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion 47:2, 206-211
CrossRef91
Charles L. Rouault. (2007) Platelet therapy is always changing. Transfusion 47:2, 192-193
CrossRef92
Yozo Nakazawa, Satoshi Saito, Yasuhisa Hasegawa, Ryu Yanagisawa, Kazuo Sakashita, Takehiko Kamijo, Toru Miyazaki, Shinichiro Sato, Hisami Ikeda, Kenji Ikebuchi, Kenichi Koike. (2007) A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia. Transfusion 47:2, 326-334
CrossRef93
Michael E. Salacz, Michael W. Lankiewicz, David E. Weissman. (2007) Management of Thrombocytopenia in Bone Marrow Failure: A Review. Journal of Palliative Medicine 10:1, 236-244
CrossRef94
S. J. Slichter. (2007) Evidence-Based Platelet Transfusion Guidelines. Hematology 2007:1, 172-178
CrossRef95
Min-Woo Jeong, Kwang-Suk Seo, Hyun-Jeong Kim, Kwang-Won Yum. (2007) Anesthetic Management of a Patient with Glanzmann's Thrombasthenia - A case report -. Korean Journal of Anesthesiology 53:3, 407
CrossRef96
B. Andemariam, B. Psaila, J. B. Bussel. (2007) Novel Thrombopoietic Agents. Hematology 2007:1, 106-113
CrossRef97
Rainer Seitz, Herbert K
nig, Johannes Dodt. 2006. Blood. .
CrossRef98
Juan Alonso‐Echanove, Brian D. Sippy, Arthur E. Chin, Lisa Cairns, Rebecca Haley, Jay S. Epstein, Michael J. Richards, Henry Edelhauser, Katrina Hedberg, Matthew J. Kuehnert, William R. Jarvis, Michele L. Pearson, . (2006) Nationwide Outbreak of Red Eye Syndrome Associated With Transfusion of Leukocyte‐Reduced Red Blood Cell Units • . Infection Control and Hospital Epidemiology 27:11, 1146-1152
CrossRef99
Avery B. Nathens, Theresa A. Nester, Gordon D. Rubenfeld, Raminder Nirula, Terry B. Gernsheimer. (2006) THE EFFECTS OF LEUKOREDUCED BLOOD TRANSFUSION ON INFECTION RISK FOLLOWING INJURY. Shock 26:4, 342-347
CrossRef100
Alan T. Tinmouth, Elisabeth Semple, Nadine Shehata, Donald R. Branch. (2006) Platelet Immunopathology and Therapy: A Canadian Blood Services Research and Development Symposium. Transfusion Medicine Reviews 20:4, 294-314
CrossRef101
Sherrill J. Slichter, Doug Bolgiano, Mary Kay Jones, Todd Christoffel, Jill Corson, Leslie Rose, Jim Foley, Mark Popovsky, Laurene L. Baril, Tammy Corda, Dorothy M. Dincecco, Edward L. Snyder. (2006) Viability and function of 8-day-stored apheresis platelets. Transfusion 46:10, 1763-1769
CrossRef102
Ralph R Vassallo, Scott Murphy. (2006) A critical comparison of platelet preparation methods. Current Opinion in Hematology 13:5, 323-330
CrossRef103
E. C. Vamvakas. (2006) The case against universal white blood cell reduction. ISBT Science Series 1:1, 64-72
CrossRef104
NANCY M. HEDDLE, RICHARD J. COOK. (2006) Design issues with clinical experimental platelet transfusion studies. Transfusion Alternatives in Transfusion Medicine 8:2, 106-113
CrossRef105
Nancy M. Heddle, Richard J. Cook, Chris Sigouin, Sherrill J. Slichter, Mike Murphy, Paolo Rebulla, . (2006) A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion 46:6, 903-911
CrossRef106
Anneke Brand, Vera Novotny, Bert Tomson. (2006) Platelet Transfusion Therapy: From 1973 to 2005. Human Immunology 67:6, 413-418
CrossRef107
M A. Blajchman. (2006) The Clinical Benefits of the Leukoreduction of Blood Products. The Journal of Trauma: Injury, Infection, and Critical Care 60:Supplement, S83-S90
CrossRef108
T. Zeiler, M. Heim, A. Dempfle, V. Kretschmer. (2006) Platelets do not adsorb HLA class I molecules during storage of pooled platelet concentrates. Transfusion Medicine 16:3, 176-183
CrossRef109
Thomas H. Price. (2006) Granulocyte transfusion therapy. Journal of Clinical Apheresis 21:1, 65-71
CrossRef110
Mark K. Fung, Karan Moore, Marilyn Ridenour, William Mook, Darrell J. Triulzi. (2006) Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery. Transfusion 46:3, 386-391
CrossRef111
Donald M. Arnold, Nancy M. Heddle, Myron Kulczycky, Julie Carruthers, Christopher Sigouin, Morris A. Blajchman. (2006) In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion 46:2, 257-264
CrossRef112
A. C. Wallgren, J. Alder, B. Andersson, A. Karlsson-Parra, A. E. Backer. (2006) The Direct Pathway of Human T-Cell Allorecognition is not Tolerized by Stimulation with Allogeneic Peripheral Blood Mononuclear Cells Irradiated with High-Dose Ultraviolet Ba. Scandinavian Journal of Immunology 63:2, 90-96
CrossRef113
E. J. Jabbour, E. Estey, H. M. Kantarjian. (2006) Adult Acute Myeloid Leukemia. Mayo Clinic Proceedings 81:2, 247-260
CrossRef114
J M Heal, J L Liesveld, G L Phillips, N Blumberg. (2005) What would Karl Landsteiner do? The ABO blood group and stem cell transplantation. Bone Marrow Transplantation 36:9, 747-755
CrossRef115
William B. Slayton, David A. Wainman, Xiao Miao Li, Zhongbo Hu, Anil Jotwani, Christopher R. Cogle, Danielle Walker, Robert C. Fisher, John R. Wingard, Edward W. Scott, Martha C. Sola. (2005) Developmental Differences in Megakaryocyte Maturation Are Determined by the Microenvironment. Stem Cells 23:9, 1400-1408
CrossRef116
Morris A. Blajchman. (2005) Landmark studies that have changed the practice of transfusion medicine. Transfusion 45:9, 1523-1530
CrossRef117
Karin Janetzko, Jean-Pierre Cazenave, Harald Kluter, Daniel Kientz, Martine Michel, Photis Beris, Bruno Lioure, Jan Hastka, Stephane Marblie, Veronique Mayaudon, Lily Lin, Jin-Sying Lin, Maureen G. Conlan, Jocelyne Flament. (2005) Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 45:9, 1443-1452
CrossRef118
Loren D. Fast. (2005) Control of immune responses induced by the transfer of allogeneic white blood cells during transfusion. Transfusion 45:s2, 44S-50S
CrossRef119
Judy H. Angelbeck, Girolamo A. Ortolano. (2005) Universal Leukocyte Reduction. Journal of Infusion Nursing 28:4, 273-281
CrossRef120
Richard J. Benjamin. (2005) Bacterial detection in platelet components and the rationale for pathogen inactivation: A blood center perspective.. Journal of Clinical Apheresis 20:2, 117-122
CrossRef121
Thomas Wagner, Sylvia E. Guber, Maria-Luise Stubenrauch, Gerhard Lanzer, Josef Neumueller. (2005) Low propidium iodide intensity in flow cytometric white blood cell counting as a marker of cell destruction?. Transfusion 45:2, 228-233
CrossRef122
Peter Schlenke. (2005) Leukocyte Reduction in Blood Component Supply: The Impact of Flow Cytometry in Assessing Residual Leukocytes. Transfusion Medicine and Hemotherapy 32:1, 12-19
CrossRef123
Hakan Ozdogu, Can Boga, Levent Oğuzkurt, Ebru Kı zı lkı lı c. (2004) Partial Splenic Embolization in Myelodysplastic Syndrome Associated with Immune Thrombocytopenia. Journal of Thrombosis and Thrombolysis 18:3, 213-216
CrossRef124
Alan Tinmouth, Ian F. Tannock, Michael Crump, George Tomlinson, Joseph Brandwein, Mark Minden, David Sutton. (2004) Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 44:12, 1711-1719
CrossRef125
M. J. Dijkstra-Tiekstra, C. E. van der Schoot, R. N. I. Pietersz, P. C. Huijgens, P. F. van der Meer, H. W. Reesink. (2004) Development of white blood cell fragments, during the preparation and storage of platelet concentrates, as measured by using real-time polymerase chain reaction. Vox Sanguinis 87:4, 250-256
CrossRef126
Ebrahim Sayeh, Rukshana Aslam, Edwin R. Speck, Hoang Le-Tien, Alan H. Lazarus, John Freedman, John W. Semple. (2004) Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype. Transfusion 44:11, 1572-1578
CrossRef127
Simon Stanworth, Chris Hyde, Nancy Heddle, Paolo Rebulla, Susan Brunskill, Michael F Murphy, Michael F Murphy. 2004. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. .
CrossRef128
D. J. van Rhenen, H. Gulliksson, J. P. Cazenave, D. Pamphilon, K. Davis, J. Flament, L. Corash. (2004) Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfusion Medicine 14:4, 289-295
CrossRef129
Dragica Paunovic, Pieter van der Meer, Jens Kjeldsen-Kragh, Riitta Kekomaki, Stella Larsson, Noemi Greppi, Laura Porretti, Bela Balint, Miroljub Trkuljic, Ninoslav Nedeljkovic, Ruzica Simonovic, Anna Massaro, Luciana Labanca, Shinichi Kora, Joachim Riggert. (2004) Multicenter evaluation of a whole-blood filter that saves platelets. Transfusion 44:8, 1197-1203
CrossRef130
Susan D. Roseff. (2004) Guidelines for Transfusion: A Way to Decrease Transfusion. Transfusion Alternatives in Transfusion Medicine 6:2, 27-36
CrossRef131
M. A. Blajchman. (2004) The top ten list of randomized controlled trials in transfusion medicine. Vox Sanguinis 87:s2, 193-196
CrossRef132
Girolamo A. Ortolano, Rosalind L. Russell, Judy A. Angelbeck, Jeffrey Schaffer, Barry Wenz. (2004) Contamination Control in Nursing With Filtration. Journal of Infusion Nursing 27:3, 157-165
CrossRef133
Paolo Rebulla, Fernanda Morelati, Nicoletta Revelli, Maria Antonietta Villa, Cinzia Paccapelo, Angela Nocco, Noemi Greppi, Maurizio Marconi, Agostino Cortelezzi, Nicola Fracchiolla, Giovanni Martinelli, Giorgio Lambertenghi Deliliers. (2004) Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. British Journal of Haematology 125:1, 83-89
CrossRef134
Dafydd Thomas, Eleftherios C. Vamvakas. (2004) Pro and Con Discussion: Universal Leukoreduction. Transfusion Alternatives in Transfusion Medicine 6:s1, 61-64
CrossRef135
G. Rock, D. Neurath, B. Toye, D. Sutton, A. Giulivi, J. Bormanis, B. Olberg, S. Holme, B. Wenz, G. Ortolano, E. Nelson. (2004) The use of a bacteria detection system to evaluate bacterial contamination in PLT concentrates. Transfusion 44:3, 337-342
CrossRef136
Justin C. Paglino, Gregory J. Pomper, Gene S. Fisch, Melanie H. Champion, Edward L. Snyder. (2004) Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 44:1, 16-24
CrossRef137
Mark K. Fung, Nalini Rao, Janet Rice, Marilyn Ridenour, William Mook, Darrell J. Triulzi. (2004) Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. Transfusion 44:1, 30-35
CrossRef138
Mark-David Levin, Mies Kappers-Klunne, Kees Sintnicolaas, Bronno van der Holt, Huub H. D. M. van Vliet, Bob Lowenberg, Mars B. van't Veer. (2004) The value of alloantibody detection in predicting response to HLA-matched platelet transfusions. British Journal of Haematology 124:2, 244-250
CrossRef139
Juliet Ho, William J. Sibbald, Ian H. Chin-Yee. (2003) Effects of storage on efficacy of red cell transfusion: When is it not safe?. Critical Care Medicine 31:Supplement, S687-S697
CrossRef140
Lawrence T. Goodnough. (2003) Risks of blood transfusion. Critical Care Medicine 31:Supplement, S678-S686
CrossRef141
Helen Enright, Kathryn Davis, Terry Gernsheimer, Jeffrey J. McCullough, Robert Woodson, Sherrill J. Slichter. (2003) Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 43:11, 1545-1552
CrossRef142
Vic Ciaravino, Tim McCullough, George Cimino. (2003) The role of toxicology assessment in transfusion medicine. Transfusion 43:10, 1481-1492
CrossRef143
Gail Rock, Doris Neurath, Nancy Cober, Marissa Freedman, Michel Leduc, Edward Nelson, Ming Lu. (2003) Seven-day storage of random donor PLT concentrates. Transfusion 43:10, 1374-1377
CrossRef144
G. Rock, C. Moltzan, A. Alharbi, A. Giulivi, D. Palmer, J. Bormanis. (2003) Automated collection of blood components: their storage and transfusion. Transfusion Medicine 13:4, 219-225
CrossRef145
(2003) Guidelines for the use of platelet transfusions. British Journal of Haematology 122:1, 10-23
CrossRef146
John A Hawkins, Neal D Hillman, Linda M Lambert, Jamison Jones, Gregory B Di Russo, Tracie Profaizer, Thomas C Fuller, L.LuAnn Minich, Richard V Williams, Robert E Shaddy. (2003) Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. The Journal of Thoracic and Cardiovascular Surgery 126:1, 247-252
CrossRef147
Samuel T. Wortham, Girolamo A. Ortolano, Barry Wenz. (2003) A brief history of blood filtration: clot screens, microaggregate removal, and leukocyte reduction. Transfusion Medicine Reviews 17:3, 216-222
CrossRef148
Alan T Tinmouth, John Freedman. (2003) Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfusion Medicine Reviews 17:3, 181-193
CrossRef149
Scott B. Cantor, Linda S. Elting, David V. Hudson, Edward B Rubenstein. (2003) Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 97:12, 3099-3106
CrossRef150
Dean Follmann, Michael Proschan, Eric Leifer. (2003) Multiple Outputation: Inference for Complex Clustered Data by Averaging Analyses from Independent Data. Biometrics 59:2, 420-429
CrossRef151
Loren D. Fast. (2003) The effect of exposing murine splenocytes to UVB light, psoralen plus UVA light, or gamma-irradiation on in vitro and in vivo immune responses. Transfusion 43:5, 576-583
CrossRef152
Michael J. Wallace, Aida Narvios, Benjamin Lichtiger, Kamran Ahrar, Frank A. Morello, Sanjay Gupta, David C. Madoff, Marshall E. Hicks. (2003) Transjugular Liver Biopsy in Patients with Hematologic Malignancy and Severe Thrombocytopenia. Journal of Vascular and Interventional Radiology 14:3, 323-327
CrossRef153
H. Mohr, A. Redecker-Klein. (2003) Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sanguinis 84:2, 96-104
CrossRef154
Saroj Vadhan-Raj, Benjamin Lichtiger, Jerome Connor. (2002) Safety and usefulness of autologous cryopreserved platelets. The Lancet 360:9349, 1986
CrossRef155
Elizabeth S. Vanderlinde, Neil Blumberg. (2002) The Cost Consequences of Universal Leukoreduction. Transfusion Alternatives in Transfusion Medicine 4:5, 178-184
CrossRef156
David H McKenna, Ted Eastlund, Miriam Segall, Harriet J Noreen, Soon Park. (2002) HLA alloimmunization in patients requiring ventricular assist device support. The Journal of Heart and Lung Transplantation 21:11, 1218-1224
CrossRef157
Paolo Rebulla. (2002) Refractoriness to platelet transfusion. Current Opinion in Hematology 9:6, 516-520
CrossRef158
K. Janatpour, T. G. Paglieroni, L. Schuller, K. Foley, T. Rizzardo, P. V. Holland. (2002) Interpretation of atypical patterns encountered when using a flow cytometry-based method to detect residual leukocytes in leukoreduced red blood cell components. Cytometry 50:5, 254-260
CrossRef159
M. Bock, S. Rahrig, D. Kunz, G. Lutze, M. U. Heim. (2002) Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfusion Medicine 12:5, 317-324
CrossRef160
V. P. Choudhry. (2002) Platelet therapy. The Indian Journal of Pediatrics 69:9, 779-783
CrossRef161
Nancy M. Heddle. (2002) Evidence-based clinical reporting: a need for improvement. Transfusion 42:9, 1106-1110
CrossRef162
Milind D. Ronghe, Annabel B. M. Foot, Jaqueline M. Cornish, Colin G. Steward, David Carrington, Nicholas Goulden, David I. Marks, Anthony Oakhill, Derwood H Pamphilon. (2002) The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. British Journal of Haematology 118:4, 1124-1127
CrossRef163
Sherrill J. Slichter. (2002) Understanding the Effects of Different Types of White Cells on Patient's Responses to Transfusion: Immunization Versus Tolerization. Vox Sanguinis 83, 421-424
CrossRef164
Laurence Corash. (2002) Confounding Variables and Co-Interventions in the Design of Clinical Trials: Real Life Experience. Vox Sanguinis 83, 261-266
CrossRef165
John W. Semple, John Freedman. (2002) Leukoreduction Just Doesn't “Take Away” Immunogenic Leukcocytes, It Creates an Immunosuppressive Leukocyte Dose.. Vox Sanguinis 83, 425-428
CrossRef166
Ajeet D. Sharma, Thomas F. Slaughter, Fiona M. Clements, Gautam Sreeram, Mark F. Newman, Barbara Phillips-Bute, Steven J. Bredehoeft, Peter K. Smith, Mark Stafford-Smith. (2002) Association of Leukocyte-Depleted Blood Transfusions with Infectious Complications after Cardiac Surgery. Surgical Infections 3:2, 127-133
CrossRef167
Terrence L. Geiger, Paul Woodard, Xin Tong, Deo Kumar Srivastava, Robyn Johnson, Victoria Turner, Gregory Hale, Stacye Richardson. (2002) Human leucocyte antigen alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia. British Journal of Haematology 117:3, 634-641
CrossRef168
Saroj Vadhan-Raj, John J Kavanagh, Ralph S Freedman, Jody Folloder, Laura M Currie, Carlos Bueso-Ramos, Claire F Verschraegen, Aida B Narvios, Jerome Connor, William K Hoots, Lyle D Broemeling, Benjamin Lichtiger. (2002) Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. The Lancet 359:9324, 2145-2152
CrossRef169
Richard J. Benjamin, Kenneth C. Anderson. (2002) What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?. Critical Reviews in Oncology/Hematology 42:2, 163-171
CrossRef170
Sheila A. Myer, Jamie Oliva. (2002) Severe Aplastic Anemia and Allogeneic Hematopoietic Stem Cell Transplantation. AACN Clinical Issues: Advanced Practice in Acute and Critical Care 13:2, 169-191
CrossRef171
Nancy M. Heddle, Morris A. Blajchman, Ralph M. Meyer, Jeff H. Lipton, Irwin R. Walker, Graham D. Sher, Lorrie A. Constantini, Bruce Patterson, Robin S. Roberts, Kevin E. Thorpe, Mark N. Levine. (2002) A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 42:5, 556-566
CrossRef172
U. Cassens, B. Greve, K. Tapernon, B. Nave, E. Severin, W. Sibrowski, W. Gohde. (2002) A novel true volumetric method for the determination of residual leucocytes in blood components. Vox Sanguinis 82:4, 198-206
CrossRef173
Jean-Fran??ois Baron, Maximilien Gourdin, Mich??le Bertrand, Anne Mercadier, Jos??e Delort, Edouard Kieffer, Pierre Coriat. (2002) The Effect of Universal Leukodepletion of Packed Red Blood Cells on Postoperative Infections in High-Risk Patients Undergoing Abdominal Aortic Surgery. Anesthesia & Analgesia 94:3, 529-537
CrossRef174
Satoshi Saito, Satoshi Ota, Hideyuki Seshimo, Yuichiro Yamazaki, Setsuo Nomura, Toshihiro Ito, Jun Miki, Masao Ota, Hirofumi Fukushima, Hiroo Maeda. (2002) Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 42:3, 302-308
CrossRef175
Chris Parshuram, John Doyle, Wendy Lau, Sam D. Shemie. (2002) Transfusion-associated graft versus host disease. Pediatric Critical Care Medicine 3:1, 57-62
CrossRef176
Kiery Braithwaite, Amal Abu-Ghosh, Lauren Anderson, Mitchell Cairo. (2002) Journal of Pediatric Hematology/Oncology 24:4, 323
CrossRef177
Sabeen Askari, Phillip R. Weik, John Crosson. (2002) Calculated platelet dose: Is it useful in clinical practice?. Journal of Clinical Apheresis 17:2, 103-105
CrossRef178
Joanne Pennington, Stephen F. Garner, Janet Sutherland, Lorna M. Williamson. (2001) Residual subset population analysis in WBC-reduced blood components using real-time PCR quantitation of specific mRNA. Transfusion 41:12, 1591-1600
CrossRef179
C.A. Schiffer. (2001) Diagnosis and management of refractoriness to platelet transfusion. Blood Reviews 15:4, 175-180
CrossRef180
Ronald G. Strauss. (2001) Economy of platelet transfusions from a hospital perspective: pricing predicates practice. Transfusion 41:12, 1617-1624
CrossRef181
Paul Ness, Sally Campbell-Lee. (2001) Current Opinion in Hematology 8:6, 392-396
CrossRef182
Thomas A. Ratko, Joseph P. Cummings, Harold A. Oberman, Kendall P. Crookston, Phillip J. DeChristopher, D. Ted Eastlund, John E. Godwin, Ronald A. Sacher, David H. Yawn, Karl A. Matuszewski. (2001) Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 41:10, 1310-1319
CrossRef183
Jean-Pierre Cazenave, Kathryn Davis, Laurence Corash. (2001) Design of clinical trials to evaluate the efficacy of platelet transfusion: The euroSPRITE trial for components treated with helinx™ technology. Seminars in Hematology 38, 46-54
CrossRef184
Paolo Rebulla. (2001) REVISITATION OF THE CLINICAL INDICATIONS FOR THE TRANSFUSION OF PLATELET CONCENTRATES. Reviews in Clinical and Experimental Hematology 5:3, 288-310
CrossRef185
Philip A. Pappalardo, Ann R. Secord, Philippe Quitevis, Marcia D. Haimowitz, Dennis Goldfinger. (2001) Platelet transfusion refractoriness associated withHPA-1a (PlA1) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 41:8, 984-987
CrossRef186
Erik J. Uhlmann, Elizabeth Isgriggs, Mary Wallhermfechtel, Lawrence T. Goodnough. (2001) Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 41:8, 997-1000
CrossRef187
Roslyn Yomtovian, Terry Gernsheimer, Susan F. Assmann, Kala Mohandas, Tzong-Hae Lee, Leslie A. Kalish, Michael P. Busch, . (2001) WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 41:8, 1030-1036
CrossRef188
Ritchard G. Cable, Richard L. Edwards. (2001) The use of platelet concentrates versus plateletpheresis-the donor perspective. Transfusion 41:6, 727-729
CrossRef189
P.L. Perrotta, E.L. Snyder. (2001) Non-infectious complications of transfusion therapy. Blood Reviews 15:2, 69-83
CrossRef190
Martin Kurz, Paul Knobl, Peter Kalhs, Hildegard T. Greinix, Paul Hocker, Simon Panzer. (2001) Platelet-reactive HLA antibodies associated with low posttransfusion platelet increments:a comparison between the monoclonal antibody-specific immobilization of platelet antigens assay and the lymphocytotoxicity test. Transfusion 41:6, 771-774
CrossRef191
Eleftherios C. Vamvakas, Morris A. Blajchman. (2001) Universal WBC reduction:the case for and against. Transfusion 41:5, 691-712
CrossRef192
Paul M. Ness, Karen Shoos Lipton. (2001) Selective transfusion protocols:errors and accidents waiting to happen. Transfusion 41:5, 713-715
CrossRef193
Richard R. Anderson, MD, FASCP, Phillip J. DeChristopher, MD, PhD. (2001) Practice Parameters for Transfusion Medicine. Laboratory Medicine 32:4, 193-204
CrossRef194
Leigh C. Jefferies, Bruce S. Sachais, Donald S. Young. (2001) Blood transfusion costs by diagnosis-related groupsin 60 university hospitals in 1995. Transfusion 41:4, 522-529
CrossRef195
Peter B. Langmuir, Richard Aplenc, Beverly J. Lange. (2001) Acute myeloid leukaemia in children. Best Practice & Research Clinical Haematology 14:1, 77-93
CrossRef196
Kim Janatpour, Paul Holland. (2001) Blood support for pediatric surgery. The Indian Journal of Pediatrics 68:2, 159-165
CrossRef197
Jean-Pierre Gelinas, Lanu V Stoddart, Edward L Snyder. (2001) Thrombocytopenia and Critical Care Medicine. Journal of Intensive Care Medicine 16:1, 1-21
CrossRef198
Lawrence Tim Goodnough. (2001) Platelet transfusion therapy. Journal of Clinical Apheresis 16:1, 43-48
CrossRef199
Lawrence T. Goodnough. (2000) The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 40:12, 1522-1527
CrossRef200
Thomas Kickler. (2000) Pretransfusion testing for platelet transfusions. Transfusion 40:12, 1425-1426
CrossRef201
Patricia M. Kopko, Paul V. Holland. (2000) Universal leukocyte reduction. Current Opinion in Hematology 7:6, 397-401
CrossRef202
M. Dean Elfath, Pamela Whitley, May S. Jacobson, Kathy Cranfill-Hupp, Donna M. Kemp, Deanna McNeil, Sherrie Sawyer, Sharon Bell-Dize, Jed B. Gorlin, Sherwin V. Kevy, Michael J. McAteer. (2000) Evaluation of an automated system for the collection of packed RBCs, platelets, and plasma. Transfusion 40:10, 1214-1222
CrossRef203
P.H. Roddie, M.L. Turner, L.M. Williamson. (2000) Leucocyte depletion of blood components. Blood Reviews 14:3, 145-156
CrossRef204
A. Brand. (2000) Immunological aspects of blood transfusions. Blood Reviews 14:3, 130-144
CrossRef205
K.R. Meehan, C.O. Matias, S.S. Rathore, S.G. Sandler, J. Kallich, J. LaBrecque, H. Erder, K.A. Schulman. (2000) Platelet transfusions: Utilization and associated costs in a tertiary care hospital. American Journal of Hematology 64:4, 251-256
CrossRef206
H. Nagahasi, K. Yabusaki, H. Matsui, T. Hirono, N. Yokokawa, M. Satake, K. Tadokoro, T. Juji. (2000) Improved Sensitivity in the Measurement of Residual Leukocytes in Platelet Products Using an Automated Leukocyte Counter. Vox Sanguinis 79:1, 34-39
CrossRef207
Andrew R. Crow, John Freedman, Barbara Hannach, Alan H. Lazarus. (2000) Monoclonal antibody-mediated inhibition of the human HLA alloimmune response to platelet transfusion is antigen specific and independent of Fcgamma receptor-mediated immune suppression. British Journal of Haematology 110:2, 481-487
CrossRef208
Douglas Coyle, Karen M. Lee, Dean A. Fergusson, Andreas Laupacis. (2000) Cost Effectiveness of Epoetin-?? to Augment Preoperative Autologous Blood Donation in Elective Cardiac Surgery. PharmacoEconomics 18:2, 161-171
CrossRef209
Lorna M. Williamson. (2000) Leucocyte Depletion Of The Blood Supply - How Will Patients Benefit?. British Journal of Haematology 110:2, 256-272
CrossRef210
P. Perseghin, L. Mascaretti, M. Riva, G. Sciorelli. (2000) Comparison of plateletpheresis concentrates produced with Spectra LRS version 5.1 and LRS Turbo version 7.0 cell separators. Transfusion 40:7, 789-793
CrossRef211
F. Ferrer, J. Rivera, J. Corral, R. Gonzalez-Conejero, M.L. Lozano, V. Vicente. (2000) Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: impact of filtration timing. Transfusion 40:7, 781-788
CrossRef212
D.J. Triulzi, E.M. Meyer, A.D. Donnenberg. (2000) WBC subset analysis of WBC-reduced platelet components. Transfusion 40:7, 771-780
CrossRef213
Rainer Seitz, Herbert König, Johannes Dodt. 2000. Blood. .
CrossRef214
F. Ferrer, J. Rivera, J. Corral, R. Gonzalez-Conejero, V. Vicente. (2000) Evaluation of Leukocyte-Depleted Platelet Concentrates Obtained by In-Line Filtration. Vox Sanguinis 78:4, 235-241
CrossRef215
J.G. Vostal, T.J. Reid, T.H. Mondoro. (2000) Summary of a workshop on in vivo efficacy of transfused platelet components and platelet substitutes. Transfusion 40:6, 742-750
CrossRef216
Ajeet D. Sharma, Gautam Sreeram, Thomas Erb, Hilary P. Grocott, Thomas F. Slaughter. (2000) Leukocyte-Reduced Blood Transfusions: Perioperative Indications, Adverse Effects, and Cost Analysis. Anesthesia & Analgesia 90:6, 1315-1323
CrossRef217
Hitoshi Ohto, Hiroyasu Yasuda, Mutsuko Yokota, Takanori Matsuoka, Tadashi Nomizu. (2000) HLA antibodies after transfusions of FFP. Transfusion 40:5, 613a-613
CrossRef218
Eduardo Delaflor-Weiss, Paul D. Mintz. (2000) The evaluation and management of platelet refractoriness and alloimmunization. Transfusion Medicine Reviews 14:2, 180-196
CrossRef219
Jeffrey McCullough. (2000) Current issues with platelet transfusion in patients with cancer. Seminars in Hematology 37, 3-10
CrossRef220
John A. Hawkins, John P. Breinholt, Linda M. Lambert, Thomas C. Fuller, Tracie Profaizer, Edwin C. McGough, Robert E. Shaddy. (2000) Class I and class II anti-hla antibodies after implantation of cryopreserved allograft material in pediatric patients. The Journal of Thoracic and Cardiovascular Surgery 119:2, 324-330
CrossRef221
Sunny Dzik, James Aubuchon, Leigh Jeffries, Steven Kleinman, Catherine Manno, Michael F. Murphy, Mark A. Popovsky, Merlin Sayers, Leslie E. Silberstein, Sherril J. Slichter, Eleftherios C. Vamvakas. (2000) Leukocyte reduction of blood components: Public policy and new technology. Transfusion Medicine Reviews 14:1, 34-52
CrossRef222
Kathleen M. Grima. (2000) Therapeutic apheresis in hematological and oncological diseases. Journal of Clinical Apheresis 15:1-2, 28-52
CrossRef223
Thomas H. Price. (2000) The current prospects for neutrophil transfusions for the treatment of granulocytopenic infected patients. Transfusion Medicine Reviews 14:1, 2-11
CrossRef224
K.J. Kao. (2000) Mechanisms and new approaches for the allogeneic blood transfusion-induced immunomodulatory effects. Transfusion Medicine Reviews 14:1, 12-22
CrossRef225
Nancy Bunin, Fred Saunders, Ann Leahey, John Doyle, Stan Calderwood, Melvin H. Freedman. (1999) Alternative Donor Bone Marrow Transplantation for Children With Juvenile Myelomonocytic Leukemia. Journal of Pediatric Hematology/Oncology 21:6, 479-485
CrossRef226
Lawrence Tim Goodnough. (1999) Alternative Strategies in Platelet Therapy. Transfusion Alternatives in Transfusion Medicine 1:3, 25-30
CrossRef227
Derwood H. Pamphilon. (1999) The rationale and use of platelet concentrates irradiated with ultraviolet-B light. Transfusion Medicine Reviews 13:4, 323-333
CrossRef228
I. Lopez-Plaza, J. Weissfeld, D.J. Triulzi. (1999) The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 39:9, 925-932
CrossRef229
M. Elfath, H. Tahhan, P. Mintz, L. Dumont, P. Whitley, S. Sawyer, D. McNeil. (1999) Quality and clinical response to transfusion of prestorage white cell-reduced apheresis platelets prepared by use of an in-line white cell-reduction system. Transfusion 39:9, 960-966
CrossRef230
A.H. Lazarus, A.R Crow, J. Freedman, V. Blanchette, B. Hannach. (1999) Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L) in severe combined immune-deficient mice engrafted with human lymphocytes. Transfusion 39:8, 818-823
CrossRef231
R. J. Benjamin, P. Rojas, S. Christmas, J. Neal, S. Broughton, C. Burgio, B. Barrett, W.H. Churchill. (1999) Plateletpheresis efficiency: a comparison of the Spectra LRS and AMICUS separators. Transfusion 39:8, 895-899
CrossRef232
R. Zimmermann, G. Wittmann, J. Zingsem, R. Blasczyk, V. Weisbach, R. Eckstein. (1999) Antibodies to private and public HLA class I epitopes in platelet recipients. Transfusion 39:7, 772-780
CrossRef233
D.V. Devine, A.J. Bradley, E. Maurer, E. Levin, S. Chahal, K. Serrano, M.I.C. Gyongyossy-Issa. (1999) Effects of prestorage white cell reduction on platelet aggregate formation and the activation state of platelets and plasma enzyme systems. Transfusion 39:7, 724-734
CrossRef234
K.B. Davis, S.J. Slichter, L. Corash. (1999) Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion 39:6, 586-592
CrossRef235
Andrew R. Crow, John Freedman, Barbara Hannach, Victor Blanchette, Alan H. Lazarus. (1999) Antibody-mediated inhibition of the human alloimmune response to platelet transfusion in Hu-PBL-SCID mice. British Journal of Haematology 104:4, 919-924
CrossRef236
Lawrence Tim Goodnough, Suhail Ali, George Despotis, Marian Dynis, John F. DiPersio. (1999) Economic Impact of Donor Platelet Count and Platelet Yield in Apheresis Products: Relevance for Emerging Issues in Platelet Transfusion Therapy. Vox Sanguinis 76:1, 43-49
CrossRef237
V.M.J. Novotny. (1999) Prevention and Management of Platelet Transfusion Refractoriness. Vox Sanguinis 76:1, 1-13
CrossRef238
Laurence Corash. (1999) Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: Current research perspectives. Transfusion Medicine Reviews 13:1, 18-30
CrossRef239
Henry M. Rinder, Kenneth A. Ault. (1998) Platelet activation and its detection during the preparation of platelets for transfusion. Transfusion Medicine Reviews 12:4, 271-287
CrossRef240
M. R. Adams, L. J. Dumont, M. McCall, W. A. Heaton. (1998) Clinical trial and local process evaluation of an apheresis system for preparation of white cell-reduced platelet components. Transfusion 38:10, 966-974
CrossRef241
Eleftherios C. Vamvakas. (1998) Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transfusion Medicine Reviews 12:4, 258-270
CrossRef242
Zimmermann, Handtrack, Zingsem, Weisbach, Neidhardt, Glaser, Eckstein. (1998) A survey of blood utilization in children and adolescents in a German university hospital. Transfusion Medicine 8:3, 185-194
CrossRef243
J.E. Menitove. (1998) Hemovigilance in the United States of America. Vox Sanguinis 74:S2, 447-455
CrossRef244
D.H. Pamphilon. (1998) The Treatment of Blood Components with Ultraviolet-B Irradiation. Vox Sanguinis 74:S2, 15-19
CrossRef245
R. Kekomäki. (1998) Use of HLA- and HPA - Matched Platelets in Alloimmunized Patients. Vox Sanguinis 74:S2, 359-363
CrossRef246
Norfolk, Ancliffe, Contreras, Hunt, Machin, Murphy, Williamson. (1998) CONSENSUS CONFERENCE ON PLATELET TRANSFUSION, ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 27-28 NOVEMBER 1997: Synopsis of background papers. British Journal of Haematology 101:4, 609-617
CrossRef247
(1998) Prophylactic Platelet Transfusions in Acute Myeloid Leukemia. New England Journal of Medicine 338:20, 1468-1470
Full Text248
Charles A. Schiffer. (1998) Opportunities for the use of thrombopoietic growth factors. Stem Cells 16:S1, 249-253
CrossRef249
Dennie V. Jones, Mark Ashby, Sue Hellmann, Gwen Fyfe, Saroj Vadhan‐Raj, Richard Champlin, James Gajewski, George Somlo. (1998) Recombinant human thrombopoietin clinical development. Stem Cells 16:S1, 199-206
CrossRef250
Napier, Chapman, Forman, Kelsey, Knowles, Murphy, Williamson, Wood, Kinsey, Murphy, Pamphilon, Warwick. (1998) Guidelines on the clinical use of leucocyte-depleted blood components. Transfusion Medicine 8:1, 59-71
CrossRef251
Lawrence Tim Goodnough, David Kuter, Jeffrey McCullough, Mark E. Brecher. (1998) Apheresis platelets: Emerging issues related to donor platelet count, apheresis platelet yield, and platelet transfusion dose. Journal of Clinical Apheresis 13:3, 114-119
CrossRef252
Kruskall, Margot S., . (1997) The Perils of Platelet Transfusions. New England Journal of Medicine 337:26, 1914-1915
Full Text
- Letters
